About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 670139, 10 pages
http://dx.doi.org/10.1155/2013/670139
Review Article

Pharmacological Treatment for Hepatopulmonary Syndrome

1Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Division of Hepato-Gastroenterology, Department of Internal Medicine, Kangnam St. Mary Hospital, Catholic University Medical College, Seoul, Republic of Korea

Received 25 April 2013; Revised 30 July 2013; Accepted 12 August 2013

Academic Editor: Kusum Kharbanda

Copyright © 2013 Ahad Eshraghian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Rodríguez-Roisin and M. J. Krowka, “Hepatopulmonary syndrome—a liver-induced lung vascular disorder,” The New England Journal of Medicine, vol. 358, no. 22, pp. 2378–2387, 2008.
  2. A. Regev, M. Yeshurun, M. Rodriguez et al., “Transient hepatopulmonary syndrome in a patient with acute hepatitis A,” Journal of Viral Hepatitis, vol. 8, no. 1, pp. 83–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Fuhrmann, C. Madl, C. Mueller et al., “Hepatopulmonary syndrome in patients with hypoxic hepatitis,” Gastroenterology, vol. 131, no. 1, pp. 69–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. K. Stoller, P. A. Lange, M. K. Westveer, W. D. Carey, D. Vogt, and J. M. Henderson, “Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation—The Cleveland Clinic experience,” Western Journal of Medicine, vol. 163, no. 2, pp. 133–138, 1995. View at Scopus
  5. G. P. Martínez, J. A. Barberà, J. Visa et al., “Hepatopulmonary syndrome in candidates for liver transplantation,” Journal of Hepatology, vol. 34, no. 5, pp. 651–657, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. M. B. Fallon, M. J. Krowka, R. S. Brown et al., “Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates,” Gastroenterology, vol. 135, no. 4, pp. 1168–1175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Dehghani, S. Aleyasin, N. Honar et al., “Pulmonary evaluation in pediatric liver transplant candidates,” Indian Journal of Pediatrics, vol. 78, no. 2, pp. 171–175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” PLoS Medicine, vol. 6, no. 7, Article ID e1000100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-Z. Tan, G. Kaley, and G. H. Gurtner, “Nitric oxide and prostaglandins mediate vasodilation to 5,6-EET in rabbit lung,” Advances in Experimental Medicine and Biology, vol. 407, pp. 561–566, 1996. View at Scopus
  10. G. Rolla, L. Brussino, P. Colagrande et al., “Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis,” Hepatology, vol. 26, no. 4, pp. 842–847, 1997. View at Scopus
  11. H. Nunes, D. Lebrec, M. Mazmanian et al., “Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 879–885, 2001. View at Scopus
  12. L. Liu, N. Liu, Z. Zhao, et al., “TNF-alpha neutralization improves experimental hepatopulmonary syndrome in rats,” Liver International, vol. 32, pp. 1018–1026, 2012.
  13. I. Cirera, T. Martin Bauer, M. Navasa, et al., “Bacterial translocation of enteric organisms in patients with cirrhosis,” Journal of Hepatology, vol. 34, pp. 32–37, 2001.
  14. P. Berthelot, J. G. Walker, S. Sherlock, and L. Reid, “Arterial changes in the lungs in cirrhosis of the liver—lung spider nevi,” The New England Journal of Medicine, vol. 274, no. 6, pp. 291–298, 1966. View at Scopus
  15. J. Zhang, W. Yang, B. Luo, B. Hu, A. Maheshwari, and M. B. Fallon, “The role of CX(3)CL1/CX(3)CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome,” Journal of Hepatology, vol. 57, pp. 752–758, 2012.
  16. K. E. Roberts, S. M. Kawut, M. J. Krowka et al., “Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease,” Gastroenterology, vol. 139, no. 1, pp. 130.e24–139.e24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Luo, G. A. Abrams, and M. B. Fallon, “Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction,” Journal of Hepatology, vol. 29, no. 4, pp. 571–578, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. D. G. Koch, G. Bogatkevich, V. Ramshesh, J. J. Lemasters, R. Uflacker, and A. Reuben, “Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans,” Digestive Diseases and Sciences, vol. 57, no. 2, pp. 516–523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Luo, L. Liu, L. Tang et al., “Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome,” Journal of Hepatology, vol. 38, no. 5, pp. 556–563, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Zabel, F. U. Schade, and M. Schlaak, “Inhibition of endogenous TNF formation by pentoxifylline,” Immunobiology, vol. 187, no. 3–5, pp. 447–463, 1993. View at Scopus
  21. Y.-M. Chen, S.-L. Lin, W.-C. Chiang, K.-D. Wu, and T.-J. Tsai, “Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases,” Kidney International, vol. 69, no. 8, pp. 1410–1415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Poulakis, G. Androutsos, D. Kazi et al., “The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications,” Respiratory Medicine, vol. 93, no. 1, pp. 52–57, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Neuner, G. Klosner, M. Pourmojib, R. Knobler, and T. Schwarz, “Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes,” Immunology, vol. 90, no. 3, pp. 435–439, 1997. View at Scopus
  24. K. Toda, N. Kumagai, F. Kaneko et al., “Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production,” Journal of Gastroenterology and Hepatology, vol. 24, no. 5, pp. 860–865, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Salhiyyah, E. Senanayake, M. Abdel-Hadi, A. Booth, and J. A. Michaels, “Pentoxifylline for intermittent claudication,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD005262, 2012.
  26. M. C. Sha and C. M. Callahan, “The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review,” Alzheimer Disease and Associated Disorders, vol. 17, no. 1, pp. 46–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Whitfield, A. Rambaldi, J. Wetterslev, and C. Gluud, “Pentoxifylline for alcoholic hepatitis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD007339, 2009. View at Scopus
  28. V. Trajković, V. Badovinac, D. Popadić, O. Hadžič, and M. M. Stojković, “Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression,” Immunology, vol. 92, no. 3, pp. 402–406, 1997. View at Scopus
  29. B. Sztrymf, A. Rabiller, H. Nunes et al., “Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats,” European Respiratory Journal, vol. 23, no. 5, pp. 752–758, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Zhang, Y. Ling, L. Tang et al., “Pentoxifylline attenuation of experimental hepatopulmonary syndrome,” Journal of Applied Physiology, vol. 102, no. 3, pp. 949–955, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Zhang, B. Luo, L. Tang et al., “Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome,” Gastroenterology, vol. 136, no. 3, pp. 1070–1080, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. B. Gupta, A. Kumar, A. K. Jaiswal et al., “Pentoxifylline therapy for hepatopulmonary syndrome: A Pilot Study,” Archives of Internal Medicine, vol. 168, no. 16, pp. 1820–1823, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. H. R. Kianifar, M. Khalesi, and E. Mahmoodi, “Afzal Aghaei M.Pentoxifylline in hepatopulmonary syndrome,” World Journal of Gastroenterology, vol. 18, no. 35, pp. 4912–4916, 2012.
  34. R. Tanikella, G. M. Philips, D. K. Faulk, S. M. Kawut, and M. B. Fallon, “Pilot study of pentoxifylline in hepatopulmonary syndrome,” Liver Transplantation, vol. 14, no. 8, pp. 1199–1203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. A. Taghavi, M. E. Membari, A. Eshraghian, S. M. Dehghani, L. Hamidpour, and F. Khademalhoseini, “Comparison of chromoendoscopy and conventional endoscopy in the detection of premalignant gastric lesions,” Canadian Journal of Gastroenterology, vol. 23, no. 2, pp. 105–108, 2009. View at Scopus
  36. S. M. Bradberry, “Occupational methaemoglobinaemia: mechanisms of production, features, diagnosis and management including the use of methylene blue,” Toxicological Reviews, vol. 22, no. 1, pp. 13–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. C. A. Paciullo, D. M. Horner, K. W. Hatton, and J. D. Flynn, “Methylene blue for the treatment of septic shock,” Pharmacotherapy, vol. 30, no. 7, pp. 702–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Marczin, U. S. Ryan, and J. D. Catravas, “Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion,” Journal of Pharmacology and Experimental Therapeutics, vol. 263, no. 1, pp. 170–179, 1992. View at Scopus
  39. A. Miyamoto, Y. Katsuta, X.-J. Zhang et al., “Effect of chronic methylene blue administration on hypoxemia in rats with common bile duct ligation,” Hepatology Research, vol. 40, no. 6, pp. 622–632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Rolla, C. Bucca, and L. Brussino, “Methylene blue in the hepatopulmonary syndrome,” The New England Journal of Medicine, vol. 331, no. 16, p. 1098, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Schenk, C. Madl, S. Rezaie-Majd, S. Lehr, and C. Muller, “Methylene blue improves the hepatopulmonary syndrome,” Annals of Internal Medicine, vol. 133, no. 9, pp. 701–706, 2000. View at Scopus
  42. V. Jounieaux, O. Leleu, and I. Mayeux, “Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome,” Intensive Care Medicine, vol. 27, no. 6, pp. 1103–1104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Roma, E. Balbi, L. Pacheco-Moreira et al., “Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report,” Transplantation Proceedings, vol. 42, no. 2, pp. 601–604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Boztosun, A. Piçnak, M. I. Kosar, S. Gulturk, and A. Cetin, “Effects of methylene blue, pentoxyphylline and enoxaparin on postoperative adhesion formation and markers of angiogenesis in a rat uterine horn model,” Clinical & Experimental Obstetrics & Gynecology, vol. 39, no. 1, pp. 89–95, 2012.
  45. N. Zacharakis, P. Tone, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou, “Methylene blue inhibits angiogenesis in chick chorioallontoic membrane through a nitric oxide-independent mechanism,” Journal of Cellular and Molecular Medicine, vol. 10, no. 2, pp. 493–498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Wiest, S. Das, G. Cadelina, G. Garcia-Tsao, S. Milstien, and R. J. Groszmann, “Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility,” Journal of Clinical Investigation, vol. 104, no. 9, pp. 1223–1233, 1999. View at Scopus
  47. E. Miot-Noirault, L. Faure, Y. Guichard, J. Montharu, and A. Le Pape, “Scintigraphic in vivo assessment of the development of pulmonary intravascular macrophages in liver disease: experimental study in rats with biliary cirrhosis,” Chest, vol. 120, no. 3, pp. 941–947, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. R. J. Panos and S. K. Baker, “Mediators, cytokines, and growth factors in liver-lung interactions,” Clinics in Chest Medicine, vol. 17, no. 1, pp. 151–170, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Nunes, D. Lebrec, M. Mazmanian et al., “Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 879–885, 2001. View at Scopus
  50. P. Gines, A. Rimola, R. Planas et al., “Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial,” Hepatology, vol. 12, no. 4 I, pp. 716–724, 1990. View at Scopus
  51. A. Rabiller, H. Nunes, D. Lebrec et al., “Prevention of Gram-negative translocation reduces the severity of hepatopulmonary syndrome,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 4, pp. 514–517, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. R. M. Añel and J. N. Sheagren, “Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents,” Clinical Infectious Diseases, vol. 32, no. 10, pp. E131–E136, 2001. View at Scopus
  53. S. Gupta, M. E. Faughnan, L. Lilly, S. Hutchison, R. Fowler, and A. M. Bayoumi, “Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial,” Clinical Gastroenterology and Hepatology, vol. 8, no. 12, pp. 1095–1098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. H. Caldwell, L. J. Jeffers, O. S. Narula, E. A. Lang, K. R. Reddy, and E. R. Schiff, “Ancient remedies revisited: does Allium sativum (garlic) palliate the hepatopulmonary syndrome?” Journal of Clinical Gastroenterology, vol. 15, no. 3, pp. 248–250, 1992. View at Scopus
  55. G. A. Abrams and M. B. Fallon, “Treatment of hepatopulmonary syndrome with Allium sativum L. (Garlic): a pilot trial,” Journal of Clinical Gastroenterology, vol. 27, no. 3, pp. 232–235, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. M. N. Sani, H. R. Kianifar, A. Kianee, and G. Khatami, “Effect of oral garlic on arterial oxygen pressure in children with hepatopulmonary syndrome,” World Journal of Gastroenterology, vol. 12, no. 15, pp. 2427–2431, 2006. View at Scopus
  57. B. K. De, D. Dutta, S. K. Pal, S. Gangopadhyay, S. D. Baksi, and A. Pani, “The role of garlic in hepatopulmonary syndrome: a randomized controlled trial,” Canadian Journal of Gastroenterology, vol. 24, no. 3, pp. 183–188, 2010. View at Scopus
  58. S. Nagae, M. Ushijima, S. Hatono et al., “Pharmacokinetics of the garlic compound S-allylcysteine,” Planta Medica, vol. 60, no. 3, pp. 214–217, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. D. D. Ku, T. T. Abdel-Razek, J. Dai, S. Kim-Park, M. B. Fallon, and G. A. Abrams, “Garlic and its active metabolite allicin produce endothelium- and nitric oxide-dependent relaxation in rat pulmonary arteries,” Clinical and Experimental Pharmacology and Physiology, vol. 29, no. 1-2, pp. 84–91, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. A. S. Mousa and S. A. Mousa, “Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53,” Nutrition and Cancer, vol. 53, no. 1, pp. 104–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Matsuura, Y. Miyamae, K. Yamane et al., “Aged garlic extract inhibits angiogenesis and proliferation of colorectal carcinoma cells,” Journal of Nutrition, vol. 136, no. 3, pp. 842S–846S, 2006. View at Scopus
  62. H. Nunes, D. Lebrec, M. Mazmanian et al., “Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 879–885, 2001. View at Scopus
  63. M. Maniscalco, M. Sofia, and T. Higenbottam, “Effects of an NO-synthase inhibitor L-NMMA in the hepatopulmonary syndrome,” Respiration, vol. 68, no. 2, p. 226, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. F. P. Gómez, J. A. Barberá, J. Roca, F. Burgos, C. Gistau, and R. Rodríguez-Roisin, “Effects of nebulized NG-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome,” Hepatology, vol. 43, no. 5, pp. 1084–1091, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. T. J. Diao, X. Chen, L. H. Deng, et al., “Protective effect of nitric oxide on hepatopulmonary syndrome from ischemia-reperfusion injury,” World Journal of Gastroenterology, vol. 18, no. 25, pp. 3310–3316, 2012.
  66. P. Durand, C. Baujard, A. L. Grosse et al., “Reversal of hypoxemia by inhaled nitric oxide in children with severe hepatopulmonary syndrome, type 1, during and after liver transplantation,” Transplantation, vol. 65, no. 3, pp. 437–439, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. P. C. H. Hollman and M. B. Katan, “Dietary flavonoids: intake, health effects and bioavailability,” Food and Chemical Toxicology, vol. 37, no. 9-10, pp. 937–942, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. A. W. Boots, G. R. M. M. Haenen, and A. Bast, “Health effects of quercetin: from antioxidant to nutraceutical,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 325–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Zeng, B. Yi, Z. Wang, J. Ning, X. Wang, and K. Lu, “Effect of annexin A2 on hepatopulmonary syndrome rat serum-induced proliferation of pulmonary arterial smooth muscle cells,” Respiratory Physiology & Neurobiology, vol. 185, no. 2, pp. 332–338, 2013.
  70. J. Tieppo, M. J. Cuevas, R. Vercelino, M. J. Tuñón, N. P. Marroni, and J. González-Gallego, “Quercetin administration ameliorates pulmonary complications of cirrhosis in rats,” Journal of Nutrition, vol. 139, no. 7, pp. 1339–1346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Tieppo, R. Vercelino, A. S. Dias et al., “Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome,” Food and Chemical Toxicology, vol. 45, no. 7, pp. 1140–1146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Miljkovic, I. Cvetkovic, S. Stosic-Grujicic, and V. Trajkovic, “Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts,” Clinical and Experimental Immunology, vol. 132, no. 2, pp. 239–246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Villarroel, M. Hidalgo, and A. Jimeno, “Mycophenolate mofetil: an update,” Drugs of Today, vol. 45, no. 7, pp. 521–532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Domhan, S. Muschal, C. Schwager et al., “Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid,” Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1656–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Moreira Silva, G. Reis, M. Guedes, et al., “A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production),” Journal of Hepatology, vol. 58, no. 3, pp. 630–633, 2013.
  76. Ş. Yilmaz, M. Dursum, F. Canoruç, K. Bayan, A. Karabulut, and H. Akay, “A severe (type II) hepatopulmonary syndrome in a patient with idiopathic portal hypertension and treatment with paroxetine,” Netherlands Journal of Medicine, vol. 63, no. 11, pp. 448–452, 2005. View at Scopus
  77. R. Iyer, G. Fetterly, A. Lugade, and Y. Thanavala, “Sorafenib: a clinical and pharmacologic review,” Expert Opinion on Pharmacotherapy, vol. 11, no. 11, pp. 1945–1955, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. C. C. Chang, C. L. Chuang, F. Y. Lee, et al., “Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis,” Clinical Science, vol. 124, no. 7, pp. 457–466, 2013.
  79. J. M. Theysohn, J. F. Schlaak, S. Müller, et al., “Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration,” Journal of Vascular and Interventional Radiology, vol. 23, no. 7, pp. 949–952, 2012.
  80. S. Krug, A. Sablotzki, S. Hammerschmidt, H. Wirtz, and H.-J. Seyfarth, “Inhaled iloprost for the control of pulmonary hypertension,” Vascular Health and Risk Management, vol. 5, no. 1, pp. 465–474, 2009. View at Scopus
  81. M. Gomberg-Maitland and I. R. Preston, “Prostacyclin therapy for pulmonary arterial hypertension: new directions,” Seminars in Respiratory and Critical Care Medicine, vol. 26, no. 4, pp. 394–401, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Krug, H.-J. Seyfarth, A. Hagendorff, and H. Wirtz, “Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia,” European Journal of Gastroenterology and Hepatology, vol. 19, no. 12, pp. 1140–1143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Vercelino, J. Tieppo, A. S. Dias et al., “N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome,” Basic and Clinical Pharmacology and Toxicology, vol. 102, no. 4, pp. 370–376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. M. J. Krowka, E. R. Dickson, and D. A. Cortese, “Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatin analogue,” Chest, vol. 104, no. 2, pp. 515–521, 1993. View at Scopus
  85. H. Ozyurt, B. Ozyurt, K. Koca, and S. Ozgocmen, “Caffeic acid phenethyl ester (CAPE) protects rat skeletal muscle against ischemia-reperfusion-induced oxidative stress,” Vascular Pharmacology, vol. 47, no. 2-3, pp. 108–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. S. Song, E.-H. Park, G. M. Hur et al., “Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity,” Cancer Letters, vol. 175, no. 1, pp. 53–61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Tekin, S. Türkyılmaz, T. Küçükkartallar, et al., “Effects of caffeic acid phenethyl ester (CAPE) on hepatopulmonary syndrome,” Inflammation, vol. 34, no. 6, pp. 614–619, 2011.